Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

The FDA has officially approved Eli Lilly’s drug Omvoh for adult use in moderately ... Click here to see the list. Don’t miss these offers — they won’t be this good forever.

Eli Lilly is set to report fourth-quarter ... revenue for the company's famous weight management drug, Zepbound. We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right ...

Eli Lilly is leading a push with other pharmaceutical companies to request a pause in the Biden administration's drug pricing negotiations, even as officials prepare to release a new list of ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers ...

Eli Lilly & Co. (LLY) thinks its next experimental ... Zepbound was only taken off the Food and Drug Administration’s drug shortage list in October, while tirzepatide — the active ingredient ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...